

NA Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 133 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the gene therapy market are:

- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy

Market Players:

The key market players for North America gene therapy market are listed below:

- AGC Biologics
- Amgen, Inc.
- AnGes, Inc
- Biogen
- bluebird bio, Inc.
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Dendreon Pharmaceuticals LLC
- Enzyvant Therapeutics GmbH
- Ferring B.V.
- Janssen Pharmaceuticals, Inc.
- Kite Pharma (a subsidiary of Gilead Sciences, Inc.)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Mallinckrodt.
- Novartis AG
- Orchard Therapeutics plc.
- Oxford Biomedica
- Spark Therapeutics, Inc.
- uniQure NV.

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	20
1.1 OBJECTIVES OF THE STUDY	20
1.2 MARKET DEFINITION	20
1.3 OVERVIEW OF THE NORTH AMERICA GENE THERAPY MARKET	20
1.4 CURRENCY AND PRICING	22
1.5 LIMITATIONS	22
1.6 MARKETS COVERED	22
2 MARKET SEGMENTATION	24
2.1 MARKETS COVERED	24
2.2 GEOGRAPHICAL SCOPE	25
2.3 YEARS CONSIDERED FOR THE STUDY	26
2.4 DBMR TRIPOD DATA VALIDATION MODEL	27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	30
2.6 MULTIVARIATE MODELLING	31
2.7 MARKET END USER COVERAGE GRID	31
2.8 PRODUCT LIFELINE CURVE	32
2.9 DBMR MARKET POSITION GRID	33
2.10 VENDOR SHARE ANALYSIS	34
2.11 SECONDARY SOURCES	35
2.12 ASSUMPTIONS	35
3 EXECUTIVE SUMMARY	36
4 PREMIUM INSIGHTS	39
4.1 PESTEL ANALYSIS	40
4.2 PORTER FIVE ANALYSIS	41
5 UPDATE ON GERMLINE GENE THERAPY	42
5.1 GERMLINE GENE THERAPY	42
6 NORTH AMERICA GENE THERAPY MARKET, MO	43
6.1 DRIVERS	45
6.1.1 NOVEL APPROACHES TO GENE THERAPY	45
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS	45
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES	46
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE	47
6.2 RESTRAINTS	47
6.2.1 HIGH COST OF GENE THERAPY	47
6.2.2 ETHICAL AND SAFETY CONCERNS	48

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2.3	COMPLEXITY OF GENE THERAPY	48
6.3	OPPORTUNITIES	49
6.3.1	RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS	49
6.3.2	RISING APPROVAL FOR GENE THERAPY PRODUCTS	49
6.4	CHALLENGES	50
6.4.1	STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS	50
6.4.2	LONG-TERM SAFETY AND EFFICACY	50
7	NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE	51
7.1	OVERVIEW	52
7.2	VIRAL VECTOR	55
7.2.1	ADENOVIRUS	56
7.2.2	RETROVIRUS	56
7.2.3	LENTIVIRUS	56
7.2.4	ADENO-ASSOCIATED VIRUS	56
7.2.5	VACCINIA VIRUS	56
7.2.6	HERPES SIMPLEX VIRUS	56
7.2.7	OTHERS	56
7.3	NON-VIRAL VECTOR	56
7.3.1	LIPOFECTION	57
7.3.2	INJECTION OF NAKED DNA	57
8	NORTH AMERICA GENE THERAPY MARKET, BY METHOD	58
8.1	OVERVIEW	59
8.2	EX-VIVO	62
8.3	IN-VIVO	62
9	NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION	64
9.1	OVERVIEW	65
9.2	ONCOLOGICAL DISORDERS	68
9.3	CARDIOVASCULAR DISEASES	68
9.4	INFECTIOUS DISEASES	69
9.5	RARE DISEASES	70
9.6	NUEROLOGICAL DISORDERS	71
9.7	OTHER DISEASES	72
10	NORTH AMERICA GENE THERAPY MARKET, BY END USER	73
10.1	OVERVIEW	74
10.2	CANCER INSTITUTES	77
10.3	HOSPITALS	77
10.4	RESEARCH INSTITUTES	78
10.5	OTHERS	79
11	NORTH AMERICA GENE THERAPY MARKET, BY REGION	80
11.1	NORTH AMERICA	81
11.1.1	U.S.	87
11.1.2	CANADA	89
11.1.3	MEXICO	91
12	NORTH AMERICA GENE THERAPY MARKET, COMPANY LANDSCAPE	93
12.1	COMPANY SHARE ANALYSIS: NORTH AMERICA	93
13	COMPANY PROFILES	94
13.1	BIOGEN	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.1	COMPANY SNAPSHOT	94
13.1.2	REVENUE ANALYSIS	94
13.1.3	COMPANY SHARE ANALYSIS	95
13.1.4	SWOT ANALYSIS	95
13.1.5	PRODUCT PORTFOLIO	96
13.1.6	RECENT DEVELOPMENT	96
13.2	KITE PHARMA	97
13.2.1	COMPANY SNAPSHOT	97
13.2.2	REVENUE ANALYSIS	97
13.2.3	COMPANY SHARE ANALYSIS	98
13.2.4	SWOT ANALYSIS	98
13.2.5	PRODUCT PORTFOLIO	99
13.2.6	RECENT DEVELOPMENT	99
13.3	NOVARTIS AG	100
13.3.1	COMPANY SNAPSHOT	100
13.3.2	REVENUE ANALYSIS	100
13.3.3	COMPANY SHARE ANALYSIS	101
13.3.4	SWOT ANALYSIS	101
13.3.5	PRODUCT PORTFOLIO	102
13.3.6	RECENT DEVELOPMENTS	102
13.4	BRISTOL-MYERS SQUIBB COMPANY.	103
13.4.1	COMPANY SNAPSHOT	103
13.4.2	REVENUE ANALYSIS	103
13.4.3	COMPANY SHARE ANALYSIS	104
13.4.4	SWOT ANALYSIS	104
13.4.5	PRODUCT PORTFOLIO	105
13.4.6	RECENT DEVELOPMENT	105
13.5	OXFORD BIOMEDICA	106
13.5.1	COMPANY SNAPSHOT	106
13.5.2	REVENUE ANALYSIS	106
13.5.3	COMPANY SHARE ANALYSIS	107
13.5.4	SWOT ANALYSIS	107
13.5.5	PRODUCT PORTFOLIO	108
13.5.6	RECENT DEVELOPMENTS	108
13.6	AGC BIOLOGICS	109
13.6.1	COMPANY SNAPSHOT	109
13.6.2	PRODUCT PORTFOLIO	109
13.6.3	RECENT DEVELOPMENT	109
13.7	ANGES, INC	110
13.7.1	COMPANY SNAPSHOT	110
13.7.2	REVENUE ANALYSIS	110
13.7.3	PRODUCT PORTFOLIO	111
13.7.4	RECENT DEVELOPMENT	111
13.8	AMGEN INC.	112
13.8.1	COMPANY SNAPSHOT	112
13.8.2	REVENUE ANALYSIS	112
13.8.3	PRODUCT PORTFOLIO	113

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.8.4 RECENT DEVELOPMENT	113
13.9 BLUEBIRD BIO, INC.	114
13.9.1 COMPANY SNAPSHOT	114
13.9.2 PRODUCT PORTFOLIO	114
13.9.3 RECENT DEVELOPMENT	114
13.10 CHIESI FARMACEUTICI S.P.A	115
13.10.1 COMPANY SNAPSHOT	115
13.10.2 REVENUE ANALYSIS	115
13.10.3 PRODUCT PORTFOLIO	116
13.10.4 RECENT DEVELOPMENT	116
13.11 DENDREON PHARMACEUTICALS LLC	117
13.11.1 COMPANY SNAPSHOT	117
13.11.2 PRODUCT PORTFOLIO	117
13.11.3 RECENT DEVELOPMENT	117
13.12 ENZYVANT THERAPEUTICS GMBH	118
13.12.1 COMPANY SNAPSHOT	118
13.12.2 PRODUCT PORTFOLIO	118
13.12.3 RECENT DEVELOPMENT	118
13.13 FERRING B.V.	119
13.13.1 COMPANY SNAPSHOT	119
13.13.2 PRODUCT PORTFOLIO	119
13.13.3 RECENT DEVELOPMENT	119
13.14 JANSSEN PHARMACEUTICALS, INC.	120
13.14.1 COMPANY SNAPSHOT	120
13.14.2 PRODUCT PORTFOLIO	120
13.14.3 RECENT DEVELOPMENT	120
13.15 MALLINCKRODT.	121
13.15.1 COMPANY SNAPSHOT	121
13.15.2 REVENUE ANALYSIS	121
13.15.3 PRODUCT PORTFOLIO	122
13.15.4 RECENT DEVELOPMENT	122
13.16 ORCHARD THERAPEUTICS PLC.	123
13.16.1 COMPANY SNAPSHOT	123
13.16.2 REVENUE ANALYSIS	123
13.16.3 PRODUCT PORTFOLIO	124
13.16.4 RECENT DEVELOPMENT	124
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.	125
13.17.1 COMPANY SNAPSHOT	125
13.17.2 PRODUCT PORTFOLIO	125
13.17.3 RECENT DEVELOPMENT	125
13.18 SIBONO	126
13.18.1 COMPANY SNAPSHOT	126
13.18.2 PRODUCT PORTFOLIO	126
13.18.3 RECENT DEVELOPMENT	126
13.19 SPARK THERAPEUTICS, INC.	127
13.19.1 COMPANY SNAPSHOT	127
13.19.2 PRODUCT PORTFOLIO	127

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.19.3 RECENT DEVELOPMENT 127
13.20 UNIQUE NV. 128
13.20.1 COMPANY SNAPSHOT 128
13.20.2 REVENUE ANALYSIS 128
13.20.3 PRODUCT PORTFOLIO 129
13.20.4 RECENT DEVELOPMENT 129
14 QUESTIONNAIRE 130
15 RELATED REPORTS 133

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

NA Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 133 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottss-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottss-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottss-international.com

www.scottss-international.com